Application of Yunnan polyphyllin G in preparation of wound repairing product

Abstract

The invention provides an application of paris polyphylla saponin G (PFV85) in the technical field of cosmetics and medicines, and provides a preparation method of the paris polyphylla saponin G (PFV85) in the technical field of cosmetics and medicines. Belongs to the technical field of cosmetics and medicines. The PFV85 (0.4 [mu] g / mL) provided by the invention can obviously improve the expression quantity of the human dermal fibroblast elastin gene Elastin under UVA radiation, and does not show obvious cytotoxicity to human fibroblasts in a concentration range of 3.2 [mu] g / mL. The PFV85 can be used for preparing medicines or cosmetics for resisting skin aging caused by UVA, repairing skin injury, reducing scar formation, repairing wounds and promoting elastin gene expression and synthesis.

Description

Technical Field

[0001] This invention belongs to the fields of cosmetics and pharmaceutical technology, specifically relating to the field of herbal medicine technology, and more specifically, to the application of Yunnan Paris saponin G in the preparation of products for combating UVA-induced skin aging, and its application in the preparation of drugs or cosmetics for combating UVA-induced skin aging, repairing skin damage, reducing scar formation, wound repair, and promoting elastin gene expression and synthesis. Yunnan Paris saponin G has the activity of promoting elastin gene expression. Background Technology

[0002] The skin is the body's main protective barrier, composed of the epidermis, dermis, and subcutaneous tissue. The dermis is mainly composed of fibroblasts and the extracellular matrix (ECM) they produce, with elastin accounting for approximately 0.6%–7.9% of the ECM [Gardeazabal L., Izeta A. Elastin and collagen fibres in cutaneous wound healing. Experimental Dermatology, 2024, 33 (3), e15052]. In ultraviolet (UV) radiation, long-wave UVA (320–400 nm) can penetrate deep into the dermis, triggering a series of pathological events, including excessive generation of reactive oxygen species (ROS), activation of matrix metalloproteinases (MMPs), and degradation of ECM components such as collagen and elastin. These processes ultimately lead to decreased skin elasticity, wrinkle formation, and impaired barrier function, necessitating effective preventative strategies [Fu B., WanY., Ma X., Chang Z., Yang X., Liu X., Wu H., Cheng S., Du M. Salmon leathercollagen peptide alleviates UVA-induced photoaging via Nrf2 / Keap1 pathway by enhancing antioxidant defense and preserving skin elasticity. FoodBioscience, 2025, 72, 107494]. Elastin is abundant in normal skin and common scars, but rarely found in hypertrophic scars or keloids [Labadie JG, Dasgeb B., Phillips TJ, Arndt K. A., What Are Scars? In Procedures in Cosmetic Dermatology: Scar Management (Second Edition), Labadie, JG; Alam, M.; Dover, JS, Eds. Elsevier:2025; pp 1-10]. The soft tissue of scars treated with pressure therapy showed significant improvement in flexibility, and the transcriptional level and expression of elastin were increased [Zhang Yixin, Chai Jun. Mechanism and clinical application of pressure therapy for scars. Chinese Journal of Burns and Wound Repair, 2025, 41 (4), 316-324].Therefore, promoting the expression of elastin genes and the synthesis of elastin is beneficial for combating skin aging caused by UVA, for repairing skin damage, and for reducing scar formation. Summary of the Invention

[0003] This invention is based on the significant activity and function of Yunnan Paris saponin G (PFV85) in promoting elastin gene expression and elastin synthesis, possessing the ability to combat UVA-induced skin aging, repair skin damage, reduce scar formation, and repair wounds. The aim is to provide an application of Yunnan Paris saponin G (PFV85) in the preparation of anti-skin aging drugs, drugs for reducing scar formation, and drugs for repairing skin damage, repairing wounds, and promoting elastin gene expression and synthesis. It also applies to the preparation of cosmetics for combating UVA-induced skin aging, repairing skin damage, and reducing scar formation, repairing wounds, and promoting elastin gene expression and synthesis. A novel preparation method for Yunnan Paris saponin G (PFV85) is also provided.

[0004] To achieve the above-mentioned objectives of the present invention, the present invention provides the following technical solution:

[0005] A method for preparing Yunnan Paris saponin G (PFV85) includes the following steps:

[0006] The dried rhizomes of Paris polyphylla were pulverized and extracted three times with 70% ethanol at 78-80 °C for 4 h, 3 h, and 3 h, respectively. The filtrate was filtered and concentrated to obtain a crude extract. The crude extract was suspended in distilled water and extracted three times with an equal volume of ethyl acetate. After recovering the solvent from the organic phase, the ethyl acetate extract was obtained. The aqueous phase was further extracted four times with an equal volume of n-butanol. After recovering the solvent from the organic phase, the n-butanol extract was obtained.

[0007] The n-butanol extract was eluted using silica gel column chromatography with a gradient of CH2Cl2-MeOH (10:1–0:1). The fractions were then combined by TLC into seven fractions: Fr. I, Fr. II, Fr. III, Fr. IV, Fr. V, Fr. VI, and Fr. VII. Fr. VII was eluted with a gradient of EtOAc-MeOH (10:1–0:1), and the fractions were then combined by TLC into four fractions: Fr. VII-1, Fr. VII-2, Fr. VII-3, and Fr. VII-4. Fr. VII-4 was further purified by RP-C. 18The chromatographic column was divided into four sections: Fr. VII-4-1, Fr. VII-4-2, Fr. VII-4-3 and Fr. VII-4-4. Fr. VII-4-1 was purified by semi-preparative HPLC after being chromatographically analyzed by Sephadex LH-20 column to obtain Yunnan Paris saponin G (PFV85).

[0008] Application of Yunnan Paris saponin G in the preparation of drugs or cosmetics that promote elastin gene expression and synthesis.

[0009] Application of Yunnan Paris saponin G in the preparation of drugs for anti-UVA-induced skin aging

[0010] Application of Yunnan Paris saponin G in the preparation of drugs that reduce scar formation.

[0011] Application of Yunnan Paris saponin G in the preparation of drugs for repairing skin damage.

[0012] Application of Yunnan Paris saponin G in the preparation of cosmetics for anti-UVA-induced skin aging.

[0013] Application of Yunnan Paris saponin G in the preparation of cosmetics for repairing skin damage.

[0014] Application of Yunnan Paris saponin G in the preparation of cosmetics that reduce scar formation.

[0015] Application of Yunnan Paris saponin G in the preparation of wound repair drugs.

[0016] Application of Yunnan Paris saponin G in the preparation of cosmetics for wound repair.

[0017] Compared with the prior art, the present invention has the following advantages.

[0018] 1. Yunnan Paris saponin G (PFV85) can significantly promote the expression of elastin gene in human dermal fibroblasts under UVA radiation at extremely low concentrations (0.4 μg / mL).

[0019] 2. Yunnan Paris saponin G (PFV85) showed no toxicity to human dermal fibroblasts within a concentration range of 3.2 μg / mL.

[0020] 3. Yunnan Paris saponin G (PFV85) has significant activity in promoting the expression of elastin genes and the synthesis of elastin. In the preparation of drugs or cosmetics that promote the expression and synthesis of elastin genes, it has pharmacological activities and functions that can combat skin aging caused by UVA, repair skin damage, reduce scar formation, and repair wounds. It can be used to prepare drugs or cosmetics with the same functions and effects. Attached Figure Description

[0021] Figure 1 A schematic diagram of the chemical structure of Yunnan Paris saponin G (PFV85).

[0022] Figure 2 The Yunnan Paris saponin G (PFV85) sample did not show significant cytotoxicity to human fibroblasts within a concentration range of 3.2 μg / mL. Detailed Implementation

[0023] The following embodiments of the present invention will further illustrate the substantive content of the present invention, but are not intended to limit the present invention.

[0024] Example 1:

[0025] Preparation of Yunnan Paris saponin G (PFV85).

[0026] 4.1 kg of dried rhizomes of *Paris rugosa* H. Li & Kurita were pulverized and extracted three times with 70% ethanol (50 L × 3) under reflux at 78–80 °C for 4 h, 3 h, and 3 h, respectively. The filtrate was filtered and concentrated to obtain a crude extract (1.4 kg). The crude extract was suspended in 16 L of distilled water and extracted three times with an equal volume of ethyl acetate. After recovering the solvent from the organic phase, the ethyl acetate extract (123.4 g) was obtained. The aqueous phase was further extracted four times with an equal volume of n-butanol. After recovering the solvent from the organic phase, the n-butanol extract (219.3 g) was obtained.

[0027] The n-butanol extract (209.2 g) was eluted using a gradient of CH2Cl2-MeOH (10:1–0:1) on silica gel column chromatography (200–300 mesh). The fractions were then combined by TLC into seven fractions: Fr. I, Fr. II, Fr. III, Fr. IV, Fr. V, Fr. VI, and Fr. VII (162.0 g). Fr. VII (162.0 g) was then eluted using a gradient of EtOAc-MeOH (10:1–0:1). The fractions were then combined by TLC into four fractions: Fr. VII-1 (0.3 g), Fr. VII-2 (6.1 g), Fr. VII-3 (22.2 g), and Fr. VII-4 (112.0 g). Fr. VII-4 (112.0 g) was further eluted by RP-C. 18The chromatographic column (MeOH-H2O, 10%–100%) was divided into four fractions: Fr. VII-4-1 (0.8 g), Fr. VII-4-2 (18.6 g), Fr. VII-4-3 (13.3 g), and Fr. VII-4-4 (56.8 g). Fr. VII-4-1 (0.8 g) was purified by Sephadex LH-20 column chromatography (MeOH) followed by semi-preparative HPLC (Agilent Zorbax RX-C8, ϕ 9.4 × 250 mm; MeCN-H2O, 20:80) to obtain compound PFV85 (29.3 mg, t). R = 11.5 min).

[0028] Example 2:

[0029] Spectroscopic data of Yunnan Paris saponin G (PFV85).

[0030] Parisyunnanoside G (PFV85): White amorphous powder, C 56 H 88 O 29 CAS No. 1369542-76-6; −42 (c 0.4, MeOH); 1 H NMR (pyridine-d5, 500 MHz) δ H : 6.38(1H, br s, H-1ʹʹ), 5.59 (1H, d, J = 8.2 Hz, H-1ʹʹʹʹʹ), 5.51 (1H, br d, J =5.8 Hz, H-6), 4.93 (1H, d, J = 7.8 Hz, H-1ʹʹʹʹ), 1.84 (3H, s, H3-27), 1.72(3H, d, J = 6.1 Hz, H3-6ʹʹ), 1.51 (3H, d, J = 6.5 Hz, H3-6ʹʹʹʹʹ), 1.33 (3H, s,H3-19), 1.04 (3H, s, H3-18); 13 C NMR (pyridine-d5, 126 MHz) δ C: 139.5 (C-5), 138.0 (C-26), 124.7 (C-6), 110.8 (C-22), 109.5 (C-25), 105.4 (gal-1ʹʹʹʹ), 105.2 (xyl-1ʹʹʹ), 103.6 (fuc-1ʹʹʹʹʹ), 101.8 (rha-1ʹʹ), 100.1 (glc-1ʹ), 88.4(glc-3ʹ), 84.4 (C-1), 83.8 (C-16), 78.4 (xyl-3ʹʹʹ), 77.7 (glc-5ʹ), 77.2 (gal-5ʹʹʹʹ), 76.4 (glc-2ʹ), 76.1 (C-24), 75.5 (gal-3ʹʹʹʹ), 74.8 (xyl-2ʹʹʹ), 74.2(rha-4ʹʹ), 73.9 (fuc-3ʹʹʹʹʹ), 73.5 (fuc-4ʹʹʹʹʹ), 72.7 (gal-2ʹʹʹʹ), 72.5 (rha-2ʹʹ, 3ʹʹ), 70.7 (fuc-2ʹʹʹʹʹ), 70.6 (xyl-4ʹʹʹ), 70.3 (gal-4ʹʹʹʹ), 70.3 (fuc-5ʹʹʹʹʹ), 70.2 (C-21), 70.0 (glc-4ʹ), 70.0 (C-24), 69.6 (rha-5ʹʹ), 69.5 (C-23),68.0 (C-3), 67.3 (xyl-5ʹʹʹ), 63.2 (glc-6ʹ), 62.4 (gal-6ʹʹʹʹ), 57.8 (C-17),56.9 (C-14), 50.2 (C-9), 43.8 (C-4), 42.8 (C-20), 41.1 (C-13), 40.0 (C-12), 38.0 (C-2), 33.0 (C-8), 32.5 (C-15), 31.8 (C-7), 24.0 (C-11), 19.3 (rha-6ʹʹ),17.0 (fuc-6ʹʹʹʹʹ), 16.8 (C-18), 15.7 (C-27), 15.1 (C-19); ESIMS m / z 1247 [M +Na] + By comparing the spectral data in the literature [Duan Xiaoyan, Yue Meicen, Yang Jun, Bai Xue, Luo Jifeng, Li Heng, Wang Yuehu. Study on chemical constituents and antibacterial activity of rhizomes of Paris polyphylla. Chinese Journal of Traditional Chinese Medicine 2023, 48 (11), 2981–2988], PFV85 was identified as parisyunnanoside G (… Figure 1 ).

[0031] Example 3:

[0032] Activity assay of PFV85:

[0033] 1. Cell

[0034] The cells used in this test were human dermal fibroblasts, batch number: Fb230131, provided by Guangdong Boxi Shaanxi Branch.

[0035] 2. Main reagents

[0036] DMEM culture medium (Gibco), fetal bovine serum (Lanzhou Rongye), PBS (Solepro), MTT (Sigma), DMSO (Sigma), AG RNAex Pro Reagent (Aikerui Biotechnology), reverse transcription kit (Aikerui Biotechnology), fluorescent dye (Aikerui Biotechnology), TGF-β1 (Peprotech).

[0037] 3. Main Equipment

[0038] CO2 incubator (Thermo, 150I), ultra-clean workbench (Sujing Antai, SW-CJ-2F), microplate reader (BioTek, Epoch), UVA irradiator (Philips), inverted microscope (Olympus, CKX53), conventional PCR instrument (Bori, TC-XP-G), and real-time PCR instrument (Roche, Lightcycler 480 II).

[0039] 4. Cytotoxicity assay based on human dermal fibroblasts

[0040] 4.1 Cell viability testing methods

[0041] 1) Cell seeding: After cell resuscitation, when the cell seeding rate reaches about 50%~60%, seed the cells into 96-well plates and incubate overnight in a CO2 incubator (37 °C, 5% CO2).

[0042] 2) Experimental Groups: The experiment included a zeroing group, a solvent control group, a positive control group, and a sample group. In the sample group, each sample had 8 concentration gradients, and each concentration gradient had 3 replicate wells.

[0043] 3) Solution preparation: Prepare working solutions of the PFV85 sample to be tested with concentrations of 0.025 μg / mL, 0.05 μg / mL, 0.1 μg / mL, 0.2 μg / mL, 0.4 μg / mL, 0.8 μg / mL, 1.6 μg / mL and 3.2 μg / mL.

[0044] 4) Drug administration: Drug administration was performed when the cell seeding rate in the 96-well plate reached 50%–60%. For the solvent control group, 200 μL of culture medium was added to each well; for the positive control group, 200 μL of culture medium containing 10% DMSO was added to each well; for the sample group, 200 μL of culture medium containing the corresponding concentration of the sample was added to each well; for the zeroing group, no cells were seeded, only 200 μL of cell culture medium was added. After drug administration, the 96-well plate was placed in a CO2 incubator (37 ℃, 5% CO2) and incubated for 24 h.

[0045] 5) Detection: After culturing cells for 24 h, discard the supernatant, add MTT working solution (0.5 mg / mL), and incubate at 37 ℃ in the dark for 4 h. After incubation, discard the supernatant, add 150 μL DMSO to each well, and read the OD value at 490 nm.

[0046] 6) Calculation of relative cell viability: According to the formula, relative cell viability (%) = [(sample well OD − zeroing well OD) / (solvent control well OD − zeroing well OD)] × 100%.

[0047] 4.2 Cell morphology testing methods

[0048] 1) Cell seeding: After cell resuscitation, when the cell seeding rate reaches about 50%~60%, seed the cells into 24-well plates and incubate overnight in a CO2 incubator (37 °C, 5% CO2).

[0049] 2) Experimental Groups: The experiment included a solvent control group and a sample group. Within the sample group, five concentration gradients were set up (0.2 μg / mL, 0.4 μg / mL, 0.8 μg / mL, 1.6 μg / mL, and 3.2 μg / mL).

[0050] 3) Drug administration: Drug administration was performed when the cell deposition rate in the 24-well plate reached 50%–60%. 1 mL of culture medium was added to each well of the solvent control group; 1 mL of culture medium containing the corresponding concentration of the test sample was added to each well of the sample group. After drug administration, the 24-well plate was placed in a CO2 incubator (37 °C, 5% CO2) and incubated for 24 h.

[0051] 4) Take photos: After incubation, discard the supernatant and take photos under an inverted microscope.

[0052] 4.3 Test Results

[0053] Based on MTT (Table 1) and morphological results ( Figure 1 Based on human fibroblasts, it was concluded that PFV85 did not exhibit significant cytotoxicity at concentrations in the range of 3.2 μg / mL.

[0054] Table 1. MTT assay results of PFV85 on human dermal fibroblasts.

[0055]

[0056] 5. Gene expression level test based on fibroblasts

[0057] 5.1 Test Method

[0058] 1) Cell seeding: After cell resuscitation, when the cell plating rate reaches about 60%, seed the cells into 6-well plates and incubate overnight in a CO2 incubator (37 °C, 5% CO2).

[0059] 2) Solution preparation: Prepare working solutions for the test substances according to the test groups.

[0060] 3) Drug administration: According to the test groups, when the cell deposition rate in the 6-well plate reached 30%~50%, drug administration was performed in groups, with 3 replicates per group. 2 mL of culture medium was added to each well of the blank control group and negative control group, 2 mL of culture medium containing the corresponding concentration of TGF-β1 was added to each well of the positive control group, and 2 mL of culture medium containing the corresponding concentration of the test sample was added to each well of the sample group. After drug administration, the 6-well plate was incubated in a CO2 incubator (37 °C, 5% CO2) for 24 h.

[0061] 4) UVA irradiation: According to the test grouping, all groups except the blank control group were subjected to UVA irradiation with an irradiation dose of 30 J / cm². 2 After irradiation, the samples were placed in an incubator (37 °C, 5% CO2) and cultured for another 24 h.

[0062] 5) Cell collection: After incubation, aspirate the old solution, wash twice with PBS, add 1 mL of AG RNAex ProReagent to each well, lyse the cells by pipetting, and collect the sample.

[0063] 6) Gene expression detection: RNA was extracted, reverse transcribed into cDNA, and then detected by real-time quantitative PCR using 2... -△△CT The method is used to calculate the results.

[0064] 7) Calculation of upward adjustment rate:

[0065] Upregulation rate (%) = [(Sample group − Blank control group) / Blank control group] × 100%

[0066] 8) Statistical Analysis of Results: GraphPad Prism Program software was used for plotting, and the results are expressed as Mean ± SD. t-tests were used for comparisons between groups. All statistical analyses were two-tailed. P < 0.05 was considered statistically significant, and P < 0.01 was considered highly statistically significant.

[0067] 5.2 Results of Elastin Gene Expression Test

[0068] The test results are shown in Table 2. Compared with the blank control (BC) group, the expression level of Elastin gene in the negative control (NC) group was significantly downregulated, indicating that the stimulation conditions of this test were effective. Compared with the NC group, the expression level of Elastin gene in the positive control (PC) group was significantly upregulated, indicating that the positive control of this test was effective. Compared with the NC group, the expression level of Elastin gene in sample PFV85 (0.4 μg / mL) was significantly upregulated (P < 0.05), with an upregulation rate of 38.71%.

[0069] Table 2. Results of Elastin gene detection

[0070]

[0071] Note: Use 2 -△△CT The method was used to calculate the results. When performing statistical analysis using the t-test method, the fold increase of mRNA in the BC group was normalized. Compared with the BC group, the significance was calculated as follows: # This means that P < 0.05 indicates that... # P < 0.01 indicates ## Compared with the NC group, significance is indicated by *, P < 0.05 is indicated by *, and P < 0.01 is indicated by **.

[0072] Example 4:

[0073] Add the excipients according to a weight ratio of 1:1 or 1:2 of Yunnan Paris saponin G (PFV85) to the excipients, then granulate and compress the mixture into tablets.

[0074] Example 5:

[0075] Tablets: Yunnan Paris saponin G (PFV85) 10mg, lactose 180mg, starch 55mg, magnesium stearate 5mg; Preparation method: Mix Yunnan Paris saponin G (PFV85), lactose and starch, moisten evenly with water, sieve and dry the moistened mixture, sieve again, add magnesium stearate, and then compress the mixture into tablets, each weighing 250 mg, with a compound content of 10 mg.

[0076] Example 6:

[0077] Capsules: Yunnan Paris saponin G (PFV85) 10 mg, lactose 187 mg, magnesium stearate 3 mg;

[0078] Preparation method: Mix Yunnan Paris saponin G (PFV85) with excipients, sieve, mix evenly, and fill the resulting mixture into hard gelatin capsules, each capsule weighing 200 mg and containing 10 mg of active ingredient.

[0079] Example 7:

[0080] Topical ointment: Melt the base ingredients (such as beeswax and coconut oil) by heating in a water bath, add Yunnan Paris saponin G (PFV85) and stir well. After cooling, put it into a sterilized sealed container and refrigerate.

[0081] Example 8:

[0082] Cream formulation containing Yunnan Paris saponin G (PFV85) (W%):

[0083] Yunnan Paris saponin G (PFV85) 0.0001

[0084] Stearic acid 8.0

[0085] C16 alcohol 2.0

[0086] Self-emulsifying monoglyceride 2.0

[0087] Hydrogenated lanolin 2.0

[0088] Liquid paraffin 12.0

[0089] Glycerin 7.0

[0090] Emulsifier 1.5

[0091] Preservative 0.2

[0092] Fragrance 0.2

[0093] Add deionized water to 100

[0094] The cosmetic product of the above-described formula of the present invention is prepared using conventional methods for manufacturing cosmetics.

[0095] Example 9:

[0096] Emulsion formulations (W%) containing Yunnan Paris saponin G (PFV85):

[0097] Yunnan Paris saponin G (PFV85) 0.0001

[0098] Stearic acid 1.4

[0099] Cetyl alcohol 0.1

[0100] 2-Ethyl alcohol cetyl stearate 1.8

[0101] Isopropyl myristate 0.2

[0102] 2-Hexyl-1-decyl alcohol 1.0

[0103] Liquid paraffin 7.5

[0104] Glycerin 3.0

[0105] Propylene glycol 8.0

[0106] Triethanolamine 1.0

[0107] Carboxyvinyl polymer 0.35

[0108] Arlacel 165 2.0

[0109] Preservative 0.2

[0110] Fragrance 0.2

[0111] Add deionized water to 100

[0112] The cosmetic product of the above-described formula of the present invention is prepared using conventional methods for manufacturing cosmetics.

[0113] Example 10

[0114] Facial cleanser containing Yunnan Paris saponin G (PFV85).

[0115] 1. Materials

[0116] The Yunnan Paris saponin G (PFV85) obtained by the same method as in Example 1 uses cosmetic-grade or food-grade raw materials.

[0117] 2. Formula

[0118] Yunnan Paris saponin G (PFV85) 0.5 g, glycerin 3.0 g, butylene glycol 3.0 g, propylene glycol 0.6 g, sodium EDTA 0.1 g, guar gum 0.3 g, zinc dioxide 2.0 g, C12-15 benzoate 4.0 g, C12-20 alkyl glucoside 3.0 g, C14-22 alcohol 0.5 g, cetearyl alcohol 1.2 g, parabens 0.2 g, sodium stearate 0.3 g, polydimethylsiloxane alcohol 0.5 g, polysorbate 0.2 g, deionized water 60 g.

[0119] 3. Preparation process

[0120] Weigh out the prescribed amount of Yunnan Paris saponin G (PFV85) and dissolve it completely in purified water; take glycerol, butylene glycol, propylene glycol, sodium EDTA, guar gum, zinc dioxide, sodium stearate, C12-15 benzoate, C12-20 alkyl glucoside, C14-22 alcohol, and cetearyl alcohol, and mix them with purified water; take parabens, polydimethylsiloxane alcohol, and polysorbate, and mix them with purified water. Mix the above-prepared solutions, stir thoroughly, and bottle to obtain the final product.

Claims

1. Application of Yunnan Paris saponin G in the preparation of drugs or cosmetics that promote elastin gene expression and synthesis.

2. Application of Yunnan Paris saponin G in the preparation of drugs for anti-UVA-induced skin aging.

3. Application of Yunnan Paris saponin G in the preparation of drugs that reduce scar formation.

4. Application of Yunnan Paris saponin G in the preparation of drugs for repairing skin damage.

5. Application of Yunnan Paris saponin G in the preparation of drugs for wound repair.

6. Application of Yunnan Paris saponin G in the preparation of cosmetics for anti-UVA-induced skin aging.

7. Application of Yunnan Paris saponin G in the preparation of cosmetics for repairing skin damage.

8. Application of Yunnan Paris saponin G in the preparation of cosmetics that reduce scar formation.

9. Application of Yunnan Paris saponin G in the preparation of cosmetics for wound repair.

10. A method for preparing Yunnan Paris saponin G, characterized in that, The method includes the following steps: The dried rhizomes of Paris polyphylla were pulverized and extracted three times with 70% ethanol at 78-80 °C for 4 h, 3 h, and 3 h, respectively. The filtrate was filtered and concentrated to obtain a crude extract. The crude extract was suspended in distilled water and extracted three times with an equal volume of ethyl acetate. After recovering the solvent from the organic phase, the ethyl acetate extract was obtained. The aqueous phase was further extracted four times with an equal volume of n-butanol. After recovering the solvent from the organic phase, the n-butanol extract was obtained. The n-butanol extract was eluted using silica gel column chromatography with a gradient of CH2Cl2-MeOH (10:1–0:1). The fractions were then combined by TLC into seven fractions: Fr. I, Fr. II, Fr. III, Fr. IV, Fr. V, Fr. VI, and Fr. VII. Fr. VII was eluted with a gradient of EtOAc-MeOH (10:1–0:1), and the fractions were then combined by TLC into four fractions: Fr. VII-1, Fr. VII-2, Fr. VII-3, and Fr. VII-4. Fr. VII-4 was further purified by RP-C. 18 The chromatographic column was divided into four sections: Fr. VII-4-1, Fr. VII-4-2, Fr. VII-4-3 and Fr. VII-4-4. Fr. VII-4-1 was purified by semi-preparative HPLC after being chromatographically analyzed by Sephadex LH-20 column to obtain Yunnan Paris saponin G.

Images